HRV inhibitors

Billions of dollars are spent in the United States alone on symptomatic relief from this disease. The ubiquitousness of this disease has led many people to seek a cure for many years (the discovery of the class of HRV inhibitors described here is over 20 years old). This chapter will describe the influence of structure-based approaches in the design of a class of antipicornaviral agents called capsid-binding inhibitors. 

---

See also in sourсe #XX -- [ , ]

See also in sourсe #XX -- [ ]

---